<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450762</url>
  </required_header>
  <id_info>
    <org_study_id>Gem/Carbo MUC01</org_study_id>
    <nct_id>NCT00450762</nct_id>
  </id_info>
  <brief_title>Gemcitabine + Carboplatin in Breast Cancer</brief_title>
  <official_title>Gemcitabine Plus Carboplatin in Patients With Pretreated Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      The rational for this trial is given by the knowledge that gemcitabine acts as a potent&#xD;
      inhibitor of DNA repair and therefore may prevent adequate repair of platin-induced DNA&#xD;
      damage. Gemcitabine is an excellent choice for combination therapy by its unique mechanism of&#xD;
      action and favourable toxicity profile. The combination of gemcitabine and cisplatin was&#xD;
      shown to be effective in several trials, producing response rates of 30-52 % in patients with&#xD;
      pretreated metastatic breast cancer. To improve on tolerability and handling of the regime&#xD;
      carboplatin may be the more appropriate choice for treatment. The mechanism of action of&#xD;
      carboplatin is very similar to that of cisplatin. The rational for combining gemcitabine and&#xD;
      carboplatin is based on their single-agent activities in metastatic breast cancer, the&#xD;
      activity of this combination in other malignancies and on the fact that carboplatin has&#xD;
      demonstrated efficacy comparable with cisplatin in several tumor types.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic breast cancer&#xD;
&#xD;
          -  All patients were required to give written informed consent.&#xD;
&#xD;
          -  Prior treatment with chemotherapy, hormonal therapy, immunotherapy or local&#xD;
             radiotherapy was allowed (except gemcitabine or platinum agents).&#xD;
&#xD;
          -  Patients were required to have at least one bidimensionally measurable lesion outside&#xD;
             a previous radiation port.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Karnofsky Performance status ≥ 70 %&#xD;
&#xD;
          -  Minimal life expectancy of 12 weeks&#xD;
&#xD;
          -  Adequate haematological, renal, cardiac and hepatic function:&#xD;
&#xD;
               1. Leukocyte count ≥ 3.0 x 109/l&#xD;
&#xD;
               2. Absolute neutrophil count ≥ 2.0 x 109/l&#xD;
&#xD;
               3. Platelet count ≥ 100 x 109/l&#xD;
&#xD;
               4. Haemoglobin ≥ 8 g/dl&#xD;
&#xD;
               5. Total serum bilirubin ≤ 1.25 x upper limit of normal (ULN) In presence of liver&#xD;
                  metastasis ≤ 3 x ULN&#xD;
&#xD;
               6. Transaminase (ALT,AST) level ≤ 3 x ULN In presence of liver metastasis ≤ 5 x ULN&#xD;
&#xD;
               7. Alkaline phosphatase level ≤ 2.5 x ULN&#xD;
&#xD;
               8. Creatinine clearance was required to exceed 60 ml/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with gemcitabine or platinum agents&#xD;
&#xD;
          -  Inadequate creatinine clearance (&lt; 60 ml/min)&#xD;
&#xD;
          -  Only bone metastases&#xD;
&#xD;
          -  Symptomatic brain metastases&#xD;
&#xD;
          -  Women who are pregnant, lactating or refuse effective contraception&#xD;
&#xD;
          -  Secondary malignancy&#xD;
&#xD;
          -  History of another primary malignant disease other than in situ carcinoma of the&#xD;
             uterine cervix or adequately treated basal cell skin cancer&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Any other concomitant severe clinical condition making implementation of the protocol&#xD;
             including pre-hydration difficult.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich - Klinikum Grosshadern</affiliation>
  </overall_official>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>March 21, 2007</last_update_submitted>
  <last_update_submitted_qc>March 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2007</last_update_posted>
  <keyword>pretreated</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

